Fig. 1

Ablation of VGlut2 mRNA and protein following CAV-Cre injection into the dorsal striatum in CAV2^Cre-Slc17a6^lox/lox mice. a Schematic representation showing the position of loxP sites inserted into the Slc17a6 locus of Slc17a6^lox/lox mice. b Illustration of needle placement for CAV2-Cre injections into CAV2^Cre-Slc17a6^+/+ controls and CAV2^Cre-Slc17a6^lox/lox mice. c Expression of VGLUT2 protein in the dorsal striatum of CAV2^Cre-Slc17a6^+/+ controls (n = 6) and CAV2^Cre-Slc17a6^lox/lox (n = 8) mice as measured by LUMINEX quantification. d Expression of Slc17a6 mRNA in the CL thalamic nucleus of CAV2^Cre-Slc17a6^+/+ controls (n = 10) and CAV2^Cre-Slc17a6^lox/lox (n = 12) mice. e Expression of Slc17a6 mRNA in the CM/PF thalamic nuclei of CAV2^Cre-Slc17a6^+/+ controls (n = 10) and CAV2^Cre-Slc17a6^lox/lox (n = 12) mice. Data in all figures are shown as mean ± standard error of mean (SEM). Statistical significance of pairwise comparison of means from CAV2^Cre-Slc17a6^+/+ controls and CAV2^Cre-Slc17a6^lox/lox mice are shown. *p < 0.05